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Specific Binding of Adamantane Drugs and Direction of their Polar
Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid
Bilayers and Dodecylphosphocholine Micelles Determined by NMR
Spectroscopy
Abstract
The transmembrane domain of the influenza M2 protein (M2TM) forms a tetrameric proton channel
important for the virus lifecycle. The proton-channel activity is inhibited by amine-containing adamantyl
drugs amantadine and rimantadine, which have been shown to bind specifically to the pore of M2TM near
Ser31. However, whether the polar amine points to the N- or C-terminus of the channel has not yet been
determined. Elucidating the polar group direction will shed light on the mechanism by which drug binding
inhibits this proton channel and will facilitate rational design of new inhibitors. In this study, we determine the
polar amine direction using M2TM reconstituted in lipid bilayers as well as dodecylphosphocholine (DPC)
micelles. 13C−2H rotational-echo double-resonance NMR experiments of 13C-labeled M2TM and methyl-
deuterated rimantadine in lipid bilayers showed that the polar amine pointed to the C-terminus of the
channel, with the methyl group close to Gly34. Solution NMR experiments of M2TM in DPC micelles
indicate that drug binding causes significant chemical shift perturbations of the protein that are very similar to
those seen for M2TM and M2(18−60) bound to lipid bilayers. Specific 2H-labeling of the drugs permitted
the assignment of drug−protein cross peaks, which indicate that amantadine and rimantadine bind to the pore
in the same fashion as for bilayer-bound M2TM. These results strongly suggest that adamantyl inhibition of
M2TM is achieved not only by direct physical occlusion of the channel, but also by perturbing the
equilibrium constant of the proton-sensing residue His37. The reproduction of the pharmacologically relevant
specific pore-binding site in DPC micelles, which was not observed with a different detergent, DHPC,
underscores the significant influence of the detergent environment on the functional structure of this
membrane protein.
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Abstract
The transmembrane domain of the influenza M2 protein (M2TM) forms a tetrameric proton
channel important for the virus lifecycle. The proton-channel activity is inhibited by amine-
containing adamantyl drugs amantadine and rimantadine, which have been shown to bind
specifically to the pore of M2TM near Ser31. However, whether the polar amine points to the N-
or C-terminus of the channel has not yet been determined. Elucidating the polar group direction
will shed light on the mechanism by which drug binding inhibits this proton channel and will
facilitate rational design of new inhibitors. In this study, we determine the polar amine direction
using M2TM reconstituted in lipid bilayers as well as DPC micelles. 13C-2H rotational-echo
double-resonance NMR experiments of 13C-labeled M2TM and methyl-deuterated rimantadine in
lipid bilayers showed that the polar amine pointed to the C-terminus of the channel, with the
methyl group close to Gly34. Solution NMR experiments of M2TM in dodecylphosphocholine
(DPC) micelles indicate that drug binding causes significant chemical shift perturbations of the
protein that are very similar to those seen for M2TM and M2(18–60) bound to lipid bilayers.
Specific 2H-labeling of the drugs permitted the assignment of drug-protein cross peaks, which
indicate that amantadine and rimantadine bind to the pore in the same fashion as for bilayer-bound
M2TM. These results strongly suggest that adamantyl inhibition of M2TM is achieved not only by
direct physical occlusion of the pore but also by perturbing the equilibrium constant of the proton-
sensing residue His37. The reproduction of the pharmacologically relevant specific pore-binding
site in DPC micelles, which was not observed with a different detergent, DHPC, underscores the
significant influence of the detergent environment on the functional structure of membrane
proteins.
Introduction
The M2 protein of the influenza A virus is a membrane-spanning tetrameric proton channel
responsible for a number of functions, including the acidification of the virion with
concomitant uncoating of the viral RNA,1,2 inhibition of autophagosome-lysosome fusion,3
filamentous virus formation and viral membrane budding and scission.4–6 This essential
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protein is the target of the adamantane class of anti-influenza drugs, amantadine (Amt) and
rimantadine (Rmt). M2 has a modular structure7 containing: 1) a short N-terminal region
that is important for the protein’s incorporation into the virion;8 2) a transmembrane (TM)
helix required for tetramerization, drug-binding and proton channel formation;7 3) an
amphiphilic cytoplasmic helix required for filamentous virion formation, budding and
ESCRT-independent membrane scission;4–6 and 4) a C-terminal tail that interacts with the
matrix protein, M1.9
Mutagenesis and electrophysiological measurements of full-length M2 in oocytes showed
that drug-resistant mutations occur at pore-lining residues (Leu26, Val27, Ala30, Ser31,
Gly34) of the N-terminal portion of the TM helix.10–13 These residues line the Amt-binding
site, as seen in the crystal structure of Amt-bound M2TM.14 Solid-state NMR (SSNMR)
distance measurements between 13C-labeled M2TM and 2H-labeled Amt in lipid bilayers15
showed that Amt exclusively bound to this site when the drug was present at a
stoichiometric concentration relative to the number of protein tetramers. However, when
Amt was in excess to the channels and formed a significant fraction of the lipid bilayer (>5
mol% of the phospholipids), it also showed dipolar interactions with Asp44 on the surface of
the four-helix bundle.15 This peripheral interaction had previously been seen in the solution
NMR structure of M2(18–60) in mixed micelles consisting of 7.5 : 1 DHPC/Rmt, which was
equivalent to a 200-fold excess of drug relative to tetramers.16 The pharmacological
relevance of the two sites was addressed by a series of electrophysiological studies10–12 that
assessed the drug sensitivities of reverse-engineered viruses in which either the peripheral
site or the pore site was mutated. These studies and other functional assays17 supported the
high-affinity binding site within the pore to be the pharmacologically relevant binding site.
There are several possible mechanisms of M2 inhibition by Amt and Rmt in the pore. First,
the location of the drug physically occludes the pore, as in the classical mechanism of
channel blockers. Second, the M2 TM domain is structurally plastic, switching between
multiple conformational states during proton conduction as well as triggered by other
environmental factors.14,18–23 Any drug that locks the protein into a single form will inhibit
the structural transitions required for ion conduction, particularly if the drug-stabilized
conformational state is a non-conducting resting state. Indeed, channel-blockers have been
known to be able to act in part via conformational selection.24,25 Finally, drug-binding was
observed to strongly perturb the acid dissociation constants (pKa’s) of the proton-sensing
His37 residues26,27 through a mechanism that has not yet been fully understood.
To elucidate the mechanism with which Amt and Rmt perturb the His37 pKa, it is important
to determine the direction of the polar moiety of these drugs. Both Amt and Rmt contain a
hydrophobic adamantyl cage connected to a polar moiety, which is an amine in Amt and
ethylamine in Rmt. Perturbation of the His37 pKa can be understood if the polar group
points down toward the C-terminus of the channel rather than up toward the N-terminus.28
However, the amine direction of these drugs has not been directly determined. In a number
of computational studies, energetically reasonable solutions for the amine up or down
directions were found, and the amine direction varied with pH and mutation of the pore-
lining residues.29–34 Experimental efforts to determine the amine direction are also
inconclusive: the crystal structure of the Amt-bound M2TM did not have sufficient
resolution (3.5 Å) to unambiguously define the amine direction, although the C-terminus-
facing direction was favored.14 The recent high-resolution SSNMR study based on cage-
perdeuterated Amt (d15-Amt) could not probe the amine direction.15 Therefore, the polar
group direction of the adamantyl drugs in the pore remains an open question; its elucidation
will be important for the design of second-generation compounds against drug-resistant
variants of M2.
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The purpose of this study is two fold. First, we determine the polar group direction of the
adamantyl drugs in the pore using solid-state NMR 13C-2H dipolar coupling measurements
in lipid bilayers. We use methyl-deuterated Rmt as the probe for the amine direction of the
drugs in the pore, and 2H quadrupolar spectra of cage-perdeuterated Rmt (d15-Rmt) to
determine the tilt angle of Rmt in the pore as well as in the lipid bilayer. Second, these solid-
state NMR measurements were complemented by isotope-edited solution NMR experiments
that show that M2TM exhibits the same specific drug-binding site in DPC micelles as in
lipid bilayers. The parallel solution and solid-state NMR experiments were motivated by the
fact that the previous solution NMR study of M2 (18–60) in DHPC micelles16 did not
observe a pore-bound drug. By comparing the NMR spectra of M2TM in micelles and in
native-like lipid bilayers, we wish to address whether detergent micelles in general perturb
the pore binding site,35 or whether it is the specific combination of the longer M2 construct
with the DHPC micelle in the previous solution NMR study16 that abolished the pore
binding site. The choice of the TM constructs for this study, rather than the longer construct
containing both the TM helix and the cytoplasmic helix, is based on the now large body of
evidence showing that the cytoplasmic helix is not required for Amt-sensitive proton
channel activities. First, electrophysiological measurements of M2TM in oocytes7 with
careful quantification of the surface expression level of the peptide showed that the single-
channel conductivity of M2TM is within a factor of two of that of the full length protein,
which revised the conclusions of an earlier study.36 Several liposome assays also showed
that M2TM conductance was 50–100% that of the full-length protein or the cytoplasmic-
helix-containing construct.7,37 Second, numerous biophysical studies showed that M2TM
was both necessary and sufficient for tetramerization in detergent micelles,14,38 and the
thermodynamics of tetramerization7,20,39–45 reproduces the unusual pKa of the essential
His37 in the full-length protein.7,27 Third, a large number of low-resolution biophysical
studies, including fluorescence,41 isothermal titration calorimetry,7 and surface plasmon
resonance 46 demonstrated that M2TM is capable of binding adamantyl drugs, and drug
binding inhibits proton translocation through M2TM channels in vesicles.7,27
Instead of mediating proton conductance, the latest reports make it clear that the cytoplasmic
helix mediates budding and release of the virus from infected cells.4–6 Simultaneous
mutation of five hydrophobic residues (F47, F48, I51, Y52, and F55) to Ala in this helix
gave rise to viruses that are defective in budding but fully capable of proton conductance as
the wild-type protein.5 Site-directed spin-labeling EPR47 and oriented solid-state NMR
data48 showed that the cytoplasmic helix is oriented parallel to and packed closely with the
plane of the bilayer, stabilized by hydrophobic interactions between residues on one face of
the cytoplasmic helix and the lipid bilayer. These findings revise the separate water-soluble
helical bundle structure reported earlier by solution NMR.16
Materials and Methods
The M2 transmembrane domain spans roughly residues 22–46. We used two slightly
different M2TM constructs in this study: M2TM(22–46) by chemical synthesis and
M2TM(19–49) by recombinant expression.
Optimized synthesis procedure for M2TM(22–46)
Due to the requirements for a large quantity of isotopically labeled peptides and the
hydrophobic nature of M2TM, we developed an optimized procedure that delivers crude
peptide with >80% purity. Problems encountered in obtaining high-yields and purity
included aspartamide formation at residue 44 and slow coupling near the center of the chain.
M2TM(22–46) with uniformly 13C, 15N-labeled V27, A30 and G34 (VAG-M2TM) was
synthesized using Fmoc chemistry at elevated temperature (75°C for both coupling and
deprotection) in a semiautomated Quest synthesizer using Rink Amide Chemmatrix resin
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(Matrix Innovation Inc, Canada). Coupling reagent were 5 eq amino acid, 5 eq HCTU, 10 eq
DIEA in NMP for 5 mins coupling. 5% piperazine and 0.1 M HOBt in DMF were used as
the deprotection solution in order to minimize aspartamide formation. The peptide was
cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O and precipitated from ether
after removal of TFA. Ether was decanted after centrifugation and the peptide was washed
with cold ether again. The final peptide was dissolved in 50% B′ (59.9% isopropanol, 30%
acetonitrile, 10% H2O, and 0.1% TFA) and 50% A (99.9% H2O, 0.1% TFA) and purified by
preparative C4 reverse phase HPLC with a linear gradient of 70% B′ to 85% B′. The peptide
was eluted at 78% B′. The purity and identify of the peptide was confirmed by analytical
HPLC (>98% purity) and MALDI-MS. Calculated MS: 2782.38, Observed MS: 2782.90.
Expression of 15N-labeled and 15N, 13C-labeled M2TM(19–49)
Uniformly 15N-labeled or 15N, 13C double labeled M2TM(19–49) for solution NMR
experiments were obtained by expressing the full-length protein in minimal medium
enriched with 1 g/L 15N NH4Cl or 1g/L 15N NH4Cl and 4g/L 13C glucose.7 The protein was
reconstituted in octylglucopyranoside (OG) micelles and digested with TPCK-treated trypsin
(Thermo Fisher), following a modification of the method described previously40 and in the
Supporting Information. The peptide was purified to homogeneity by reverse phase HPLC,
and its purity and identity confirmed by analytical HPLC, MALDI-MS, and high resolution
ESI-MS. Analytical data are provided in the Supporting Information.
Synthesis of two deuterated rimantadine compounds
1-adamantane-d15-carboxylic acid was purchased from C/D/N isotopes Inc. CD3Li in
diethyl ether was purchased from Sigma-Aldrich. 1D 1H and 13C NMR spectra were
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per
million (ppm) and referenced to the residual solvent (CD3OD or CDCl3) signals. The
following abbreviations were used in reporting the NMR spectra: s: singlet, t: triplet, m:
multiplet, p: pentet. All reactions were carried out under a N2 atmosphere unless otherwise
stated. HPLC grade solvents were used for all reactions. Column chromatography was
performed using silica gel (230–400 mesh). ESI mass spectra were obtained on a 3200 Q
Trap LC/MS/MS system (Applied Biosystem).
Synthesis of CD3-rimantadine
Intermediate I (Scheme 1): A solution of 0.5 M CD3Li (44ml, 22mmol) in diethyl ether was
added dropwise to an ice-bath cooled solution of 1-adamantane carboxylic acid (1.8 g, 10
mmol) in diethyl ether (50 ml) with stirring. The mixture was stirred at 0°C for 30 minutes,
and then continued at ambient temperature for 4 hrs. The reaction mixture was slowly
poured into a vigorously stirring solution of 1N HCl (100 ml) in ice water bath. Ether (50
ml) was added to the solution and the layers were separated, the aqueous layer was further
extracted three times with diethyl ether. The combined ether layers were extracted with
aqueous NaHCO3 and dried with MgSO4. The solvent was removed under reduced pressure
and the crude product was purified by silica gel flash column chromatography (5–10% ethyl
acetate/hexane) to give intermediate I as a white solid (1.57 g, Yield: 88%). 1H NMR (360
MHz, CDCl3) δ 2.06 (br s, 3H), 1.79–1.65 (m, 12H); 13C NMR (90 MHz, CDCl3) δ 214.21,
46.63, 38.40, 36.73, 28.12; The calculated mass for C12H15OD3 (M + H)+ is 182.3, Found
182.5.
A solution of Intermediate I (181 mg, 1 mmol), NH2OH•HCl (208.5 mg, 3 mmol) and
CH3COONa (328.1 mg, 4 mmol) in anhydrous EtOH (5 ml) was heated to reflux for 2 hrs.
The solvent was removed under reduced pressure and the residue was dissolved in CH2Cl2
and extracted with H2O twice. The organic layer was dried with MgSO4 and the solvent was
removed under reduced pressure to give the oxime intermediate. Without further
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purification, the oxime was dissolved in anhydrous THF (10 ml) and cooled to 0°C with an
ice-water bath. LiAlH4 (0.4 g, 10.5 mmol) was added portion-wise to the stirring mixture.
The solution was warmed to ambient temperature and heated to reflux for 4 hrs. The
reaction was quenched by sequential addition of 0.4 ml H2O, 0.4 ml 15% NaOH solution
and 1.2 ml H2O. The resulting slurry was filtered and the solvent was removed by rotary-
evaporation under reduced pressure. 4 M HCl in 1,4-dioxane (1 ml) was added to the oily
residue and the solvent was removed again under reduced pressure to give a white solid
crude product, which was subsequently purified by silica gel flash column chromatography
(10–20% CH3OH/CH2Cl2) to yield CD3-rimantadine as a yellow solid (164 mg, Yield:
75%). 1H NMR (360 MHz, CD3OD) δ 2.86 (br s, 1H), 2.03 (br s, 3H), 1.74–1.60 (m,
12H); 13C NMR (90 MHz, CD3OD) δ 57.90, 38.74, 37.65, 35.29, 29.30; The calculated
mass for C12H19ND3 (M + H)+ is 183.3, Found 183.7. (The 13C NMR experiment did not
use 2H decoupling, so the signal of the CD3 carbon was not detected due to splitting by
deuterons.)
Synthesis of d15-Rimantadine
The synthesis procedure of d15-rimantadine was the same as described above except starting
with 1-adamantane-d15-carboxylic acid and CH3Li.
Intermediate II: 1H NMR (360 MHz, CDCl3) δ 2.09 (s, 3H); 13C NMR (90 MHz, CDCl3) δ
214.16 (s), 46.04 (s), 37.50 (p, J = 18.0 Hz), 35.40 (p, J = 18.0 Hz), 27.12 (t, J = 18.9 Hz),
24.34 (s); The calculated mass for C12H4OD15 (M + H)+ is 194.3, Found 194.3.
D15-rimantadine: 1H NMR (360 MHz, CD3OD) δ 2.91 (s, 3H), 1.26 (s, 3H); 13C NMR (90
MHz, CD3OD) δ 58.06 (s), 37.63 (p, J = 18.0 Hz), 36.37 (p, J = 18.0 Hz), 34.89 (s), 28.27
(t, J = 18.9 Hz), 13.65 (s); The calculated mass for C12H7ND15 (M + H)+ is 195.3, Found
195.8.
Solution NMR experiments
Solution NMR spectra were recorded at 313 K on a Varian INOVA 500 MHz spectrometer
with a conventional probe, and 600 MHz and 900 MHz spectrometers equipped with
cryogenic 1H{13C, 15N}-triple resonance probes. 15N TROSY-HSQC, 13C HSQC, 2D
H(N)CA, 2D (H)C(C)H-TOCSY spectra49 were collected for backbone and sidechain
resonance assignment of 15N, 13C-labeled VAG-M2TM. 2D (13C)-NOESY spectra with a
200 ms mixing time were acquired to identify 1H–1H NOE between the peptide and Amt or
Rmt. Spectra were processed with the program NMRPipe.50 Prior to Fourier transformation,
time domain data were multiplied by sine square bell window functions shifted by 90° and
zero-filled once. 1H chemical shifts were referenced to the residual water signal while 13C
and 15N chemical shifts were indirectly referenced to DSS.
Rimantadine titration and analysis of binding isotherm—A sample of 0.94 mM
M2(19–49) in DPC (peptide/detergent molar ratio 1:50) was titrated stepwise with Rmt at
313 K and 15N-1H HSQC spectra recorded on a Bruker DMX-600 spectrometer. The
integrated intensity for the cross-peaks associated with the drug-bound form of V27, V28,
A30, I32, I35, G34, L38, I39, and I40 were determined and plotted against the concentration
of drug added. The integrated intensities were normalized such that the maximal value was
1.0 for each resonance, and the entire data set was analyzed by the method of non-linear
least squares fitting to a binding isotherm using the following equation:
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in which Iobs and Isat are the intensities at a given drug concentration and at saturating drug
concentration; [Tetra]T is the total peptide concentration divided by four, [Rmt]T is the total
drug concentration, N represents the number of drugs per tetrameter, and KD is the
dissociation constant. To explore the stoichiometry, we performed a number of calculations.
Initially N was either fixed to 1 or 4, and the value of KD was treated as a variable. Only a
value of N = 1 gave a reasonable fit to the data. Alternatively, N and KD were both allowed
to vary, which resulted in a value of N = 0.88 ± 0.04. We attribute the small difference from
1.0 to error in determining the peptide concentration and/or incomplete reconstitution of the
sample. Because [Tetra]T is significantly greater than KD for the interaction, the precise
value of this parameter could not be determined. Satisfactory fits to the data were obtained
in successive curve-fits in which this value was less than or equal to approximately 5 μM
(supplementary information).
Membrane-bound M2TM samples for solid-state NMR
Residue-specifically labeled M2TM(22–46) for SSNMR experiments was synthesized by
PrimmBiotech (Cambridge, MA) and purified to >95% purity. Uniformly 13C, 15N-labeled
amino acids were incorporated at residues Val27, Ser31, Gly34 and Asp44 (VSGD-M2TM).
Unlabeled peptides were used for static 2H quadrupolar echo experiments that detect Rmt
dynamics and orientation. M2TM(22–46) was reconstituted into 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) vesicles by OG dialysis.51 The final peptide/lipid molar
ratio was 1 : 8. A pH 7.5 phosphate buffer (10 mM Na2HPO4/NaH2PO4, 1 mM EDTA, 0.1
mM NaN3) was used to prepare the lipid vesicle solutions. The protein-lipid solutions were
dialyzed at 4°C for three days with 5–6 buffer changes to remove the detergent. Protein-lipid
precipitates usually formed after one day of dialysis. The proteoliposome mixtures were
centrifuged at 150,000 g to obtain ~40% hydrated membrane pellets for SSNMR
experiments. d15-Rmt or CD3-Rmt was dissolved in water and directly titrated into the
membrane pellet. For 13C-2H REDOR experiments, CD3-Rmt was added at a ratio of 1
drug/tetramer or 5 drugs/tetramer, which corresponded to drug/lipid molar ratios of 1 : 60 or
1 : 12, respectively. For static 2H NMR experiments, d15-Rmt was added to unlabeled
M2TM at 1 drug/tetramer and 4 drugs/tetramer ratios. Excess water after the addition of Rmt
was evaporated by placing the rotor uncapped in a dessicator at room temperature for
several hours.
Solid-state NMR experiments
Static 2H quadrupolar echo experiments were carried out on a 14.1 T wide-bore solid-state
NMR spectrometer (Bruker Biospin) operating at a 2H Larmor frequency of 92.12 MHz
using a double-resonance 4 mm 1H/2H probe. The quadrupole-echo experiment involved a
pre-echo delay of 40–50 μs, an 8 μs shorter post-echo delay, and a 2H 90° pulse length of
3.8 μs. The time signal was left-shifted appropriately to capture the echo maximum to give
Fourier-transformed spectra with flat baselines. The spectra were measured from 243 K to
303 K. The number of scans ranged from 30,000 to 150,000.
13C-detected and 2H-dephased REDOR experiments were carried out using a triple-
resonance 4 mm 1H/13C/2H magic-angle-spinning (MAS) probe on a 9.4 T wide-bore
SSNMR spectrometer (Bruker Biospin) operating at a 13C resonance frequency of 100.71
MHz and a 2H frequency of 61.48 MHz. The samples were spun under 4250 Hz MAS at 243
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K, where the protein was immobile but the drug remained dynamic. The REDOR
experiment involved a single selective 13C 180°-pulse in the center of the mixing period and
multiple 2H 180° pulses of 12.4 μs every half a rotor period. This version of the REDOR
experiment removes 13C-13C scalar coupling and thus gives long 13C T2 relaxation times,
which allows the detection of dephasing effects at long mixing times. An alternative
REDOR version containing a single 2H composite 90°90°90° pulse and multiple 13C hard
180° pulses was also conducted at one mixing time to confirm the dipolar dephasing (data
not shown). Although the second experiment produces quantitative dephasing,15 the
complex dynamics of the rotating methyl group attached to a uniaxially diffusing adamantyl
cage prohibits distance quantification from the dephasing curve, thus we did not attempt to
measure multiple REDOR time points using the latter experiment.
Static 2H lineshapes of d15-Rmt were simulated using MATLAB and the software
EXPRESS.52 For each molecular orientation of Rmt, a 4 : 1 area ratio of two couplings with
a 1 : 3 splitting ratio was maintained to represent the equatorial and axial deuterons of the
adamantyl cage. Since the effect of uniaxial diffusion on the quadrupolar coupling is known
analytically, the coupling values were directly inputted into the EXPRESS program to
generate the Pake patterns. Fitting the measured spectrum yielded the ratio between different
orientations of Rmt in the channel pore versus in the bilayer.
Results and Discussion
Amt and Rmt binding to M2TM in DPC micelles
We measured the location of Amt and Rmt bound to M2TM in DPC micelles using solution
NMR. To evaluate the effect of drug binding on the structure of the M2TM tetramer, we
first examined uniformly 15N-labeled and 13C, 15N-labled M2TM(19–49), which was
prepared by controlled proteolysis of the native, full-length protein expressed in bacteria.
We explored the spectroscopic properties of M2TM(19–49) using DPC micelles, because
the tetramerization, affinity, and stoichiometry of drug binding to various fragments of M2
had been extensively evaluated in this detergent micelle.7,40,41 Thus, it was possible to
choose conditions where M2TM(19–49) was predominantly tetrameric. In addition to Amt
and Rmt, we also examined a spiro-piperidine inhibitor WJ10, which had been shown to
bind to M2TM strongly and perturb its conformation in a similar fashion as the adamantyl
drugs.53 Fig. 1a shows the 15N-1H HSQC spectrum of M2TM(19–49) in the absence of
drug, which showed limited peak dispersion. Addition of the spiro-piperidine inhibitor53 and
Amt (Fig. 1b, Fig. S1) into the sample resulted in the appearance of a new set of
significantly sharper resonances in slow exchange with the resonances of the unbound
species. Confirming the observations of SSNMR,21 drug binding stabilized a slowly
exchanging conformer that is in low abundance in the absence of the drug (Fig. S2).
The drug-bound conformation shows large chemical shift changes of the resonances
throughout the peptide relative to the unbound form. In particular, drug binding perturbed
the chemical shifts of Val27, Ala30 and Gly34 (Fig. S3, S4) as well as the aromatic
resonances of His37 and Trp41 away from their frequencies typically seen in proteins (Fig.
1, Fig. S2). The changes are especially pronounced in the 1H dimension, in which the
dispersion of the amide 1H chemical shifts increased by 2-fold (Fig. 1), indicating the
formation of a uniquely folded tertiary structure. The increased spectral dispersion is similar
to that seen upon titration of the drug into M2TM 51,54 or M2(18–60) 23 in phospholipid
bilayers, but contrasts with the minimal changes seen when the drug was titrated into
M2(18–60) in DHPC micelles 16
To determine the stoichiometry of binding, we monitored the intensity of the drug-bound
peaks as a function of the total Rmt concentration. The 15N-1H cross peaks of nine different
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amides were sufficiently well dispersed to allow unambiguous measurement of their
intensities. A plot of the normalized integrated peak volume relative to the volume seen at
saturating drug concentration increased linearly with drug concentration until one equivalent
of drug per tetramer has been added, after which no further increase was observed. Fig. 2a
shows curves generated assuming a stoichiometry of either one or four drugs per tetramer; a
satisfactory fit is obtained only for the 1 drug/tetramer complex. To further examine the
stoichiometry and affinity of the complex, the data were analyzed using equation 1. Least
squares analysis of the data indicated a stoichiometry close to 1 drug/tetramer (N = 0.9).
Because the titration was conducted at protein concentrations that are significantly above the
KD it is difficult to obtain a precise value for this parameter. However, a sensitivity analysis
(Fig. S5) indicated that the value of KD was less than or equal to 5 μM under these
conditions.
The specific location of Amt and Rmt in M2TM(22–46) was investigated using 13C-edited
NOESY experiments. Due to the difficulty of conducting half-filtered experiments on fast-
relaxing proteins in detergent micelles, we opted to measure difference spectra of the
peptides in the presence of deuterated versus protonated drugs. Two sets of experiments
were carried out to detect NOE signals between the drug and 13C-labeled residues, one
comparing protonated versus perdeuterated Amt, and the other comparing protonated versus
CD3-labeled Rmt. Three residues in the pore binding site - Val27, Ala30 and Gly34 - were
labeled with 13C and 15N. Any NOEs from the protonated drugs to these residues that
disappear upon deuteration represent specific drug-protein interactions. Fig. 3 shows 13C-
edited NOESY spectra for protonated and perdeuterated Amt. The drugs were not 13C-
labeled, thus the only cross-peaks associated with the drug must result from interactions
with the 13C-labeled residues of the protein, and drug-drug NOEs cannot exist in the spectra.
We observed a strong NOE cross-peak at ~0.7 ppm in the direct dimension and ~1.6 ppm in
the indirect dimension, which was assigned to the γCH3 of Val27 and the C4 methylene
protons of Amt (Fig. S6). This cross peak indicates that the hydrophobic cage of Amt points
up to the N-terminus while the polar amine points down, consistent with the SSNMR result
of cage-perdeuterated Amt 15 and the X-ray structures14 of the complex, in which the
sidechain of Val27 forms a hydrophobic lid of the binding site, interacting with the apolar
portion of the drug. It is also consistent with the fact that Val27 forms closer contacts with
the adamantyl cage than Ala30 in both the crystal and SSNMR structures (Fig. 3D).
To probe the polar group direction of Rmt in the pore, we performed the same 13C-edited
NOESY experiments of the peptide bound to CD3-labeled Rmt versus protonated Rmt. Fig.
3B shows a weak NOE cross peak between the β CH3 of Ala30 and Rmt CH3. Taken
together, these NOESY difference experiments indicate that both Amt and Rmt bind in the
channel pore with the amine pointing towards the C-terminus in DPC-bound M2TM
tetramers.
Adamantyl cage orientations of Rmt in DMPC-bilayer-bound M2TM(22–46)
To determine the Rmt orientation and dynamics in M2TM reconstituted in lipid bilayers,
which better represent the virus envelope, we measured the 2H spectra of d15-Rmt.
Rimantadine consists of a rigid adamantyl cage attached to an ethylamine. Similar to Amt,
the adamantyl cage has a three-fold symmetric axis ZM. Three axial C–D bonds are parallel
to ZM while twelve equatorial C-D bonds lie at 70° or 110° from ZM. Fast uniaxial rotation
or CN jumps (N ≥ 3) of the cage around ZM results in quadrupolar splittings of 40 and 125
kHz with a 4 : 1 intensity ratio. If the drug undergoes additional fast diffusion about the
bilayer normal n⃗ with a tilt angle θnM from the molecular axis, then both equatorial and axial
couplings will be further scaled by an order parameter, Smol = (3cos2 θnM − 1)/2.55,56 Apart
from the axial rotation, wobble of the molecular axis from the bilayer normal is an
alternative motional model that is particularly relevant when Smol is large, corresponding to
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when the molecular axis lies close to the motional axis. This diffusion in a cone model
scales the couplings according to Smol = cosθnM (1+cosθnM)/2. For simplicity, below we
assume the axial rotation model in the analysis of the 2H quadrupolar spectra. While the
adamantyl cage moiety is identical between Rmt and Amt, the different polar functionality
between the two drugs can affect the molecular orientation, as we show below.
Fig. 4 shows the 2H spectra of d15-Rmt under varying drug : channel ratios from 243 K to
303 K. Three membrane samples were examined: Rmt bound to DMPC bilayers in the
absence of M2TM, in the presence of a stoichiometric number of channels (1 drug/tetramer),
and in 4-fold excess of the number of channels (4 drugs/tetramer). At 243 K, all three
samples exhibited quadrupolar splittings of ~35 kHz and ~120 kHz, consistent with the
frequency ratio expected when the adamantyl cage uniaxially rotates around its own
molecular axis. The slight reduction of the splittings from 40 and 125 kHz give Smol ≈ 0.9,
which indicates that ZM is tilted by 13° from the bilayer normal in the axial rotation model.
These 243 K spectra of Rmt are identical to the spectra of d15-Amt at the same temperature.
15
When the membranes warmed to the liquid-crystalline phase at 303 K, the 2H spectra
differed for the three samples. The lipid-only sample showed two splittings of 11.4 kHz and
35 kHz, which corresponded to Smol of ±0.28, indicating that the adamantyl cage is tilted
from the bilayer normal by 44° (or 67°) at physiological temperature (Fig. 4d). Simulation of
the 303 K spectrum confirmed the intensity and frequency ratios of the underlying Pake
patterns that represent the equatorial and axial deuterons (Fig. 5a). The 44° tilt angle of
lipid-bound Rmt is significantly larger than the 37° found for Amt.15 We hypothesize that
the bifurcated ethylamine interacts differently with the bilayer in order to better position the
polar moiety with respect to the negatively charged phosphate groups on the membrane
surface, thus the molecule adopts a different tilt angle from Amt.
When a stoichiometric amount of M2 tetramers was present, the 303 K spectrum changed
qualitatively from the lipid-only sample: the 36 kHz splitting of the equatorial deuterons at
243 K persisted to 303 K across the membrane phase transition, and dominated the spectral
intensity (Fig. 4b). The persistence of this large coupling at high temperature is similar to
what was observed for Amt15 and indicates that a significant fraction of Rmt cannot deviate
from the upright orientation due to confinement by the channel (Fig. 4e), and the drug is
well isolated from the disordered liquid-crystalline membrane. In addition to the 36-kHz
splitting, a 13.3 kHz splitting and an isotropic peak were detected in the stoichiometric
spectrum at 303 K. The former corresponds to Smol = 0.33 or θnM = 42°, which can be
attributed to Rmt in the lipid bilayer, since the amphipathic drug has affinity to both the
lipids and the aqueous pore of the channel. The fact that the splitting is 2 kHz larger than the
11.4 kHz value seen in the lipid-only sample (Fig. 4a) translates to only a small (~2°)
reduction in the tilt angle, because the order parameter has the highest angular sensitivity at
45°. The isotropic peak, which was also observed for Amt,15 may result from randomly
tumbling drug that escaped into the inter-bilayer aqueous phase, or from pore-bound drug
tilted at the magic angle (54.7°) from the channel axis. The fractions of the three
components were found by simulation (Fig. 5b) to be 63% : 27% : 10% for the 13°-tilted
channel-bound component, the 42°-tilted lipid-bound component (13.3 kHz), and the
isotropic component. The lipid-bound fraction of 27% is higher than the 10% fraction for
Amt,15 suggesting that Rmt has slightly higher affinity for the membrane than Amt under
the molar ratios used in these solid-state NMR samples.
Fig. 4c shows the 2H spectra when Rmt is in four-fold excess to the M2TM tetramers and
accounting for 8 mol% of the lipid membrane. The 303 K spectrum is now dominated by a
12.5 kHz splitting and a small 36-kHz component for the equatorial deuterons. Thus, the
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excess drug adopts a similarly tilted orientation as the lipid-bound drug in the absence of the
protein, while the drug inside the pore retained the same upright orientation as in the
stoichiometric sample.15 Simulation (Fig. 5c) yielded a ratio of 13% : 83% : 4% for the 36
kHz, 12.5 kHz and isotropic components.
Taken together, these 2H spectra indicate that the majority of the first equivalent of Rmt
adopts a nearly upright orientation in the pore of the channel, identical to Amt. Excess Rmt
has a very tilted orientation of 42–43° from the bilayer normal, which is nearly identical to
the 44° tilt of the drug in the lipids in the absence of the protein. Compared to Amt, Rmt has
a slightly different equilibrium constant between the high-affinity pore-binding site and the
low-affinity lipid-binding site, which is likely a result of the slightly different
hydrophobicity and size of the two drugs.
Binding locations and polar group direction of Rmt in the M2TM pore
Protein chemical shift perturbation provides independent evidence of ligand binding sites.
To confirm the binding locations inferred from the 2H spectra and to compare M2-Rmt
interactions with M2-Amt interactions, we measured the 13C and 15N chemical shifts of
several key residues in M2TM. Ser31, Val27 and Gly34 are the respective center and
boundaries of the pore binding site for Amt,15,51 while Asp44 probed the interaction of the
drug with the lipid-exposed binding site. Fig. 6 shows 2D 15N-13C correlation spectra of
VSGD-M2TM(22–46) in the absence and presence of Rmt. The drug-free peptide shows
two Ser31 peaks and two Gly34 15N peaks, whose relative intensities changed with titration
of the drug: the downfield 15N peaks of each residue increased in intensity upon Rmt
binding. The bound Ser31 15N peak is 6 ppm downfield from the unbound peak, while the
bound Gly34 15N peak is 3 ppm downfield from the unbound peak. These peak
displacements are very similar to those observed for Amt-bound M2TM,15,51 strongly
suggesting that Rmt also binds to the N-terminal pore near Ser31. The fact that the bound
Ser31 conformation is already present in the drug-free state indicates that Rmt shifts the
conformational equilibrium of the protein to the bound state rather than inducing an entirely
new conformation. This observation is consistent with the concept of conformational
selection by ligands, which has been documented for many globular proteins57 and has also
been reported for M2TM.18 The Val27 Cα chemical shift decreased by 2.5 ppm upon Rmt
binding. In comparison, the Asp44 15N chemical shift did not change between the apo
sample and the stoichiometric sample (both at 118.4 ppm), but increased by 1.5 ppm (at
119.9 ppm) in the sample containing excess Rmt. Thus, only excess drug affects the Asp44
conformation, providing strong evidence that the first equivalent of drug binds elsewhere
from Asp44.
13C{2H} REDOR experiments using CD3-Rmt provided definitive proof of not only the
binding location of the drug but also the direction of the amine in the pore. If the ethylamine
points to the N-terminus of the channel, significant REDOR effect will be expected for
Val27 sidechains, whereas if the amine points to the C-terminus, significant REDOR
dephasing should be detected for Gly34. Since the Rmt 2H spectra and the 2D 15N-13C
spectra of the protein with varying drug concentrations both indicate that excess Rmt does
not remove the high-affinity pore binding site, we focused the 13C{2H} REDOR experiment
on the 5 drugs/tetramer sample. Fig. 7 shows the REDOR control (S0) and dephased (S)
spectra measured with a single 13C 180° pulse and multiple 2H pulses.58 Val27 Cγ1
exhibited no dephasing at 16.9 ms, and the combined Ser31 and Val27 Cα peak at 61.4 ppm
also showed no dephasing (S/S0 = 1.02 ± 0.03 at 15.1 ms), indicating that both 13C-labeled
residues are outside dipolar contact of the deuterated methyl group. In contrast, significant
dephasing was observed for Gly34 Cα with an S/S0 value of 0.81 ± 0.04 at 18.8 ms. Thus,
the REDOR spectra indicate unambiguously that the ethylamine lies near Gly34 and points
to the C-terminus of the channel, in the direction of the His37.
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Fig. 7b also shows moderate dephasing of Asp44 Cα to 0.89 ± 0.03 at 15.1 ms, indicating
that at a lipid/drug molar ratio of 6.4 : 1, Rmt is in dipolar contact with the surface-exposed
Asp44, similar to Amt 15. Both Rmt and Amt are amphiphilic molecules and partition into
the membrane-water interface of lipid bilayers,59 at approximately the same depth as Asp44.
Thus, drug binding to Asp44 can be attributed to the high concentration of the drugs in the
bilayer and the preference of the drugs for the glycerol interfacial region of the membrane.
Additional REDOR experiments of the 1 drug/tetramer sample (Fig. 8) exhibited no
significant dephasing for the four residues within experimental uncertainty, which is
expected for Val27, Ser31 and Asp44. The lack of strong dephasing for Gly34 is partly due
to incomplete occupancy of the drug in the pore: 27% of the Rmt is in the bilayer and 10%
has vanishing quadrupolar coupling (Fig. 4), thus making ~37% of the drug unable to cause
dipolar dephasing. In addition, we suspect the peptide conformation may slightly differ
between low and high drug concentrations due to changes in the membrane viscosity and
lateral pressure, such that the height of the CD3 group may be slightly different between
stoichiometric and excess drug concentrations. Previously we did not observe different
REDOR dephasing between the stoichiometric and drug-excess complexes between d15-
Amt and M2TM.15 However, d15-Amt contains a large number of deuterons distributed over
a 2.2 Å vertical distance, which would minimize the effects of small displacements of the
drug in the pore. In contrast, the current CD3-mt contains only three deuterons concentrated
in a small volume of space, thus even subtle changes of the drug height in the pore could
significantly weaken the REDOR dephasing.
Excess drug and other membrane composition changes are known to have significant effects
on the conformational dynamics of M2TM.18,19,56,60 For example, the addition of
cholesterol at lower concentrations than the Rmt amount used here causes significant
changes in the thermodynamic stability44 and structure21 of the protein. Relaxation NMR
data revealed that the uniaxial diffusion of M2TM tetramers in DLPC bilayers was sped up
by excess Amt in the membrane,61 suggesting that the tetramers adopt tighter conformations
due to the indirect influence of the drug on the membrane fluidity. Thus, the first equivalent
of Rmt may be bound deeper in the pore, with the ethylamine outside the detectable (~5 Å)
distance range of Gly34. As excess Rmt partitioned into the membrane, the tetramers may
tighten slightly, pushing the drug up in the channel so that the CD3 group approached
Gly34, giving measurable dipolar dephasing.
The downward orientation of the polar amine in the pore confirms that the adamantane
drugs inhibit the M2 proton channel activity not only by steric block and dehydration of the
channel,22 but also by indirect drug-His37 interactions. The C-terminus-pointing amine
would be able to form hydrogen bonds with the clusters of water molecules near His37.38
These water-mediated H-bonds would tend to reduce the His37 pKa, as shown for Amt-
bound M2TM in 15N chemical shift measurements.26 The perturbation of His37 pKa is
relevant to inhibition, because it increases the fraction of the protein in the high-pH form
and decreases dynamic processes believed to be required for proton conduction.14,18,62–64
In a new spiro-piperidine inhibitor of M2 with 10-fold higher potency than Amt, methyl
substitution of the amine was found to reduce the potency significantly, indicating the
importance of the polar moiety.53
Conclusions
The solid-state and solution NMR results shown here collectively demonstrate that Rmt
binds the M2TM channel in a very similar fashion to Amt. At the stoichiometric drug
concentration, Rmt binds inside the pore with the molecular axis roughly parallel to the
bilayer normal. The polar group points towards the C-terminus, supporting the notion that
Cady et al. Page 11
J Am Chem Soc. Author manuscript; available in PMC 2012 March 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the drug inhibits the proton conductance not only by interrupting the water wire leading to
His37,30,65 but also by forming water-mediated H-bonds with His37, thus perturbing its
pKa. The proximity of the methyl group to the Gly34 backbone also suggests that the higher
affinity of Rmt to M2 than Amt 66 may result from better space filling of the drug in the
channel and dehydration of the additional hydrophobic methylene and methyl groups. This
insight suggests that new drugs to target resistant variants of the M2 protein may involve
side groups that similarly access the space near Gly34. The dynamics of Rmt inside the pore
suggests two possible strategies in the design of new M2 inhibitors. In one strategy, one can
design molecules that better fill the channel, leading to molecules with high potency for not
only the wild type but also the drug-resistant mutants V27A and L26F, as will be reported
elsewhere. Alternatively, one can also adopt the strategy of retaining the molecular
dynamics as a potential mode of conformational stabilization. The new structural
information obtained here has informed both strategies.
This study not only extends the previous structural findings of Amt to Rmt, but also
provides unique information about the polar group direction, which was absent in all
previous high-resolution structures of the M2 protein.1,15 The fundamental similarity of Rmt
and Amt in their binding locations, as well as subtle differences in their lipid interactions,
provides a rare opportunity to examine the entire distribution of bound states, including the
lipid-bound as well as protein-bound states. These data give essential information to test and
improve molecular dynamics protocols for simulating the kinetic steps involved in binding a
hydrophobic drug to a membrane protein receptor
The fact that Amt binds specifically to the pore of M2TM in DPC micelles in solution and
cause chemical shift changes that are consistent with the effects of drug on M2TM51,54 and
M2(18–60)23 in lipid bilayers, but distinct from the effects of drug on M2(18–60) in DHPC
micelles,16 underscore the importance of the environment to the functional structure of the
protein and the mutual influence that can exist between the protein and detergent micelles.35
The high-resolution orientational structure of the cytoplasmic helix recently determined by
solid-state NMR in lipid bilayers64 differ significantly from the structure in DHPC micelles.
How exactly the cytoplasmic helix affects specific drug binding in the TM pore in a
detergent environment remains an open question for future investigation.
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Figure 1.
2D 15N TROSY-HSQC spectra of 1 mM (monomer concentration) M2TM(19–49) in the
absence (a) and presence (b) of 2.5 mM WJ10. The spectra were measured at 313 K in 100
mM DPC micelle (50 mM sodium phosphate, pH 7.5, in 10% D2O and 90% H2O) on a
cryoprobe-equipped Varian INOVA 600 MHz NMR. Upon drug binding, the signals
became better dispersed in the 1H dimension, and the improved lineshape and uniformity of
the linewidths indicate that the bound protein adopts a well-folded conformation.
Assignments are labeled for the bound protein and inset shows an expanded view of part of
the spectrum. The chemical structure of spiro-piperidine WJ10 (IC50 = 0.92 μM) is shown in
the spectrum on the right. For comparison, Amt has an IC50 = 16 μM.53.
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Figure 2.
Titration of 0.94 mM M2(19–49) (monomer concentration) by Rmt. The intensities of the
indicated peaks from the 15N 1H HSQC spectra are plotted as a function of Rmt
concentration. The curve has a well-defined break at a molar ratio of one drug/tetramer
shown in blue in panel A. The corresponding titration curve expected for tight binding of the
drug in a 4 drugs/tetramer complex is shown in red. Panel B shows a least-squares fit, in
which the stoichiometry and KD were allowed to vary, as described in Methods. The curve
was generated using best-fit parameters of 0.88 ± 0.04 drug/tetramer and KD = 3.9 μM. A
sensitivity analysis (Fig. S1) showed that the value of KD was less than or equal to 5 μM
under these conditions, although it was not possible to obtain a precise value for KD under
these conditions. Data were collected at 313 K, pH 7.5, in DPC (protein : DPC ratio 1:50),
50 mM sodium phosphate buffer.
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Figure 3.
Upfield region of 2D 13C-edited 1H NOESY spectra with 200 ms mixing of 13C, 15N-
labeled VAG-M2TM with 2 eq Amt (A) and Rmt (B). The left spectra are those of
protonated drugs, and the middle spectra are from samples containing perdeuterated Amt
and methyl-deuterated Rmt. The right spectra are the difference between the left and middle
spectra. (C) The protons that show NOE cross peaks with M2 are highlighted in red in the
Amt and Rmt structures. Spectra in (A) and (B) were recorded on a 500 MHz and a 600
MHz spectrometer, respectively. The concentrations were 2 mM peptide, 100 mM DPC, 1
mM Amt or Rmt, and pH 7.5 phosphate buffer as in Fig. 3. The methyl groups of Val were
not stereospecifically assigned. (D) The structure of Amt bound in the channel pore in the
crystal structure of M2TM 14, viewed from the C-terminal end. Shown in balls are Gly34 Cα
(orange), Val27 sidechains (green), and Ala30 sidechains (cyan). The hydrophobic
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adamantyl cage (magenta) interacts extensively with the Val27 sidechains, while the polar
group (blue) points to the C-terminus in the crystal structure.
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Figure 4.
Static 2H quadrupolar echo spectra of d15-Rmt for determining the tilt angle of the
adamantyl cage in M2TM (residues 22–46) channels versus lipid bilayers. (a) d15-Rmt
bound to DMPC bilayers without the protein. (b) d15-Rmt bound to M2TM in DMPC
bilayers with 1 drug/tetramer. (c) d15-Rmt bound to M2TM with 4 drugs/tetramer. (d) One
of the two degenerate orientations of d15-Rmt in lipid bilayers at 303 K. (e) Orientation of
d15-Rmt in M2TM channels at 303 K.
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Figure 5.
Simulations of the 2H spectra of d15-Rmt at 303 K. Top row: experimental spectra
reproduced from Fig. 5. Bottom row: simulated spectra. (a) d15-Rmt bound to DMPC
bilayers without M2. Simulation used a 4 : 1 area ratio of the small and large couplings,
consistent with the number of equatorial and axial deuterons in the adamantyl cage. (b) d15-
Rmt bound to M2 at 1 drug/tetramer. Simulated spectrum used an area ratio of 63% : 27% :
10% for the 36 kHz, 13.3 kHz, and isotropic components, which represent the pore bound,
lipid bound and isotropic drugs. (c) d15-Rmt bound to M2(22–46) at 4 drugs/tetramer.
Simulated spectrum used an area ratio of 13% : 83% : 4% for the 36 kHz, 12.5 kHz and
isotropic components.
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Figure 6.
2D 15N-13C correlation spectra of Val27, Ser31, Gly34 and Asp44-labeled M2TM in DMPC
bilayers without and with Rmt. (a) The spectrum of drug-free peptide. (b) The spectrum of
the 1 drug/tetramer sample. (c) The spectrum of the 5 drugs/tetramer sample. Ser31 and
Gly34 15N chemical shift increases and Val27 Cα chemical shift decreases upon drug
binding.
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Figure 7.
13C{2H} REDOR spectra of DMPC-bound M2TM with CD3-Rmt at 5 drugs/tetramer.
Intensity difference between the control (S0, black) and dephased spectra (S, red) indicate
proximity of the 13C-labeled residues to the deuterated methyl group. (a) 16.9 ms REDOR
spectra of Val27 Cγ1 showing S/S0 = 1.02 ± 0.04. (b) 15.1 ms REDOR spectra of Ser31 Cα
(S/S0 = 1.02 ±0.03) and Asp44 Cα (S/S0 = 0.89 ± 0.03). (c) Gly34 Cα REDOR spectra at
18.8 ms, with S/S0 = 0.81 ± 0.04. The difference spectrum is shown in blue. (d) Schematic of
rimantadine structure in the pore, with the polar amine pointing to the C-terminus and the
adamantyl cage tilted by ~13°.
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Figure 8.
13C{2H} REDOR spectra of M2TM in DMPC bilayers with CD3-Rmt at 1 drug/tetramer. (a)
15.1 ms REDOR spectra. S/S0 values are 1.2±0.16 for Val27 Cγ1, 1.00 ± 0.19 for Ser31 Cα,
and 0.92 ± 0.08 for Asp44 Cα. (b) 16.9 ms REDOR spectra of Gly34 Cα. S/S0 = 0.94 ± 0.07.
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Scheme 1.
Synthetic scheme for CD3-rimantadine and d15-rimantadine.
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